alexa Helen McShane | OMICS International
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 

Helen McShane

Helen McShane, The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford, UK

Biography

Prof. Helen McShane is a Wellcome Trust Senior Clinical Research Fellow and Professor of Vaccinology at the University of Oxford. She is also a consultant HIV physician. Since 2001, she has led a research group focussed on mycobacterial immunity and the development of new vaccines for tuberculosis.
Her research programme involves design of candidate vaccines against TB, testing in various preclinical models, and extensive clinical testing through first-in-man clinical trials to field efficacy trials. MVA85A, one of the vaccines she developed, was the first subunit vaccine to undergo field efficacy testing since BCG. She collaborates with several research groups in Africa in the conduct of clinical trials including the South African TB Vaccine Initiative and the Clinical Infectious Diseases Research Institute, both at the University of Cape Town, Chu Le Dantec in Senegal and The MRC Laboratories in Uganda and The Gambia. Her current interests are in immuno-monitoring in clinical trials, the development of human mycobacterial challenge models and aerosol delivery of vaccines.

Research Interest

Tuberculosis, Vaccine, Immunisation and Clinical Trial, Mycobacterial immunity, Infectious Diseases.

Publications

Differential Cytokine Levels in Adults Induced by a Novel Candidate TB Boost Vaccine, MVA85A-According to Previous BCG Vaccination Status

Patrick K. Owiafe, Philip C. Hill, Hannah B. Ibanga, Roger H. Brookes, Helen McShane, Jayne S. Sutherland and Martin O.C. Ota

Research Article: J Vaccines Vaccin 2012, 3: 158

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7